Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lockwood

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Biopharmaceutics & Drug Disposition|April 1, 1984
Comparative bioavailability study of two tablet formulations of cimetidineR R Berardi, I A Cohen, M L Hyneck, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 18, 2009
kappa-Opioid receptors control the metabolic response to a high-energy diet in miceTraci A Czyzyk, Ruben Nogueiras, John F Lockwood, et al.
Chemistry and Physics of Lipids|June 1, 2005
Hydrophilic carotenoids: surface properties and aqueous aggregation of a rigid, long-chain, highly unsaturated dianionic bolaamphiphile with a carotenoid spacerBente Jeanette Foss, Hans-Richard Sliwka, Vassilia Partali, et al.
Scientific Reports|September 30, 2021
New spinosaurids from the Wessex Formation (Early Cretaceous, UK) and the European origins of SpinosauridaeChris T Barker, David W E Hone, Darren Naish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 30, 2013
Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesisTraci A Czyzyk, Jessica L Andrews, Tamer Coskun, et al.
Pharmacogenetics|December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrationY S Lin, G F Lockwood, M A Graham, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Thrombosis Research|August 24, 2010
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse modelSanjoy K Khan, Tadeusz Malinski, R Preston Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Biopharmaceutics & Drug Disposition|April 1, 1984
Comparative bioavailability study of two tablet formulations of cimetidineR R Berardi, I A Cohen, M L Hyneck, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 18, 2009
kappa-Opioid receptors control the metabolic response to a high-energy diet in miceTraci A Czyzyk, Ruben Nogueiras, John F Lockwood, et al.
Chemistry and Physics of Lipids|June 1, 2005
Hydrophilic carotenoids: surface properties and aqueous aggregation of a rigid, long-chain, highly unsaturated dianionic bolaamphiphile with a carotenoid spacerBente Jeanette Foss, Hans-Richard Sliwka, Vassilia Partali, et al.
Scientific Reports|September 30, 2021
New spinosaurids from the Wessex Formation (Early Cretaceous, UK) and the European origins of SpinosauridaeChris T Barker, David W E Hone, Darren Naish, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Phase I pharmacokinetic study of the novel antitumor agent SR233377P M LoRusso, B J Foster, A Wozniak, et al.
American Journal of Physiology. Endocrinology and Metabolism|May 30, 2013
Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesisTraci A Czyzyk, Jessica L Andrews, Tamer Coskun, et al.
Pharmacogenetics|December 12, 2001
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentrationY S Lin, G F Lockwood, M A Graham, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Thrombosis Research|August 24, 2010
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse modelSanjoy K Khan, Tadeusz Malinski, R Preston Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Pageof 8